Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022-Reference-Cited by-同舟云学术

Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022

Published:2023-12-20 Issue: Volume: Page:
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Kamat Samir¹,Ungar Benjamin²,Agarwal Aneesh¹,Wan Joy³,Ross Joseph S.⁴,Gupta Ravi⁵

Affiliation:

1. Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York

2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

3. Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland

4. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

5. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract

This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2812731/jamadermatology_kamat_2023_ld_230026_1701449676.22426.pdf

Reference6 articles.

1. New drugs and new molecular entities in dermatology.;Eaglstein;Arch Dermatol,2011

2. Topical drug innovation from 2000 through 2014.;Walter;JAMA Dermatol,2015

3. Approvals and timing of new formulations of novel drugs approved by the US Food and Drug Administration between 1995 and 2010 and followed through 2021.;Gupta;JAMA Health Forum,2022

4. Added therapeutic benefit of top-selling brand-name drugs in Medicare.;Egilman;JAMA,2023

5. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate.;Chen;JAMA Intern Med,2019